Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer

Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer

Abstract A population pharmacokinetic (PK)–pharmacodynamic (PD) model was developed using data from 345 patients with cancer. The population PK‐PD model evaluated the effect of erdafitinib total and free plasma concentrations on serum phosphate concentrations after once‐daily oral continuous (0.5–12...

Full description

Bibliographic Details
Main Authors: Anne‐Gaëlle Dosne, Elodie Valade, Kim Stuyckens, Peter De Porre, Anjali Avadhani, Anne O’Hagan, Lilian Y. Li, Daniele Ouellet, Ruben Faelens, Quentin Leirens, Italo Poggesi, Juan Jose Perez Ruixo
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12727

Internet

https://doi.org/10.1002/psp4.12727

Similar Items